Akeso, Inc. (HKG:9926)
108.70
+2.40 (2.26%)
Sep 30, 2026, 4:08 PM HKT
Akeso Employees
Akeso had 4,082 employees as of June 30, 2026. The number of employees increased by 321 or 8.53% since the number was reported on December 31, 2025.
Employees
4,082
Change
321
Growth
8.53%
Revenue / Employee
975.85K HKD
Profits / Employee
-273.53K HKD
Market Cap
100.13B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 4,082 | 321 | 8.53% |
| Dec 31, 2025 | 3,761 | 726 | 23.92% |
| Dec 31, 2024 | 3,035 | 257 | 9.25% |
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| WuXi Biologics | 14,705 |
| Innovent Biologics | 8,754 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
| Shanghai Junshi Biosciences | 3,055 |
Akeso News
- 3 days ago - Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer - PRNewsWire
- 10 days ago - Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals - CNBC
- 14 days ago - Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate - PRNewsWire
- 17 days ago - Big Pharma Is Pouring Billions Into China's Biotechs - Barrons
- 18 days ago - Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026 - PRNewsWire
- 4 weeks ago - Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's - PRNewsWire
- 5 weeks ago - Akeso Earnings release: H1 2026 - Filings
- 5 weeks ago - Akeso Quarterly report: H1 2026 - Filings